Anette-Gabriele Ziegler

from Wikipedia, the free encyclopedia

Anette-Gabriele Ziegler (born June 13, 1958 in Munich ) is a German doctor and has been the director of the Institute for Diabetes Research (IDF) at the Helmholtz Zentrum München since 2010. Since 2011 she has held the chair for diabetes and gestational diabetes at the Klinikum rechts der Isar of the Technical University of Munich .

Life

Ziegler began studying medicine in Munich in 1978, passed her medical state examination at the Ludwig Maximilians University there in 1984 and obtained her license to practice medicine. She received her PhD in 1986 with a paper on cellular immune phenomena in the manifestation of type I diabetes. From 1987 to 1989 she was a research fellow at the Department for Immunology, Joslin Diabetes Center, Harvard University, Boston, USA, and participated on the establishment of the immunology working group at the Institute for Diabetes Research in Munich.

In 1991 Ziegler received her recognition as an internist, in 1992 she was granted the license to teach internal medicine. Also in 1992 she was awarded the Ferdinand Bertram Prize of the German Diabetes Society. The following year she received a Heisenberg grant from the German Research Foundation at the Institute for Diabetes Research in Munich and continued her work as a senior physician at Schwabing Hospital. In 1995 Ziegler received her recognition as a diabetologist. In 2002 she turned down an offer as a C4 professor in Bochum . Since 2003 she has been a member of the board of the Munich Research Group and since 2007 its chairman.

Ziegler acts as clinical director of the Helmholtz Diabetes Center (HDC) at the Helmholtz Zentrum München . Since 2016 she has also been the spokesperson for type 1 diabetes at the German Center for Diabetes Research e. V. (DZD), also on the campus of the Helmholtz Zentrum München. There she leads a series of large-scale studies on type 1 diabetes, such as the pilot project Fr1da, which is ongoing under the patronage of the Bavarian State Minister for Health and Care, Melanie Huml. The Fr1da study was the world's first population-wide screening test for type 1 diabetes and is aimed at children between the ages of two and five years. In several preventive intervention studies, Ziegler is also researching how clinically manifest type 1 diabetes can be prevented or delayed in people at risk. With the data of the birth cohort BABYDIAB, which Ziegler established in 1989 as the world's first prospective diabetes birth cohort, she was able to uncover the susceptibility to the development of an autoimmunity associated with type 1 diabetes in the first two years of life as well as biomarkers for diagnosing an asymptomatic early stage.

Ziegler is one of the European initiators of the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD), which was founded in 2015. GPPAD pursues the goal of implementing primary prevention studies that should reduce the occurrence of beta cell autoimmunity and thus the incidence of type 1 diabetes in the long term.

Awards

  • Ferdinand Bertram Prize of the German Diabetes Society (1992)
  • Dr. Bürger-Büsing Prize from the German Diabetes Union (1994)
  • Ernst Friedrich Pfeiffer Prize of the German Diabetes Society (1998)
  • Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award from the Juvenile Diabetes Research Foundation (JDRF) (2013)
  • Dr. Michael Brownlee Lecture Award from the Joslin Diabetes Center at Harvard Medical School in Boston (2014)
  • Werner Creutzfeldt Prize of the German Diabetes Society (2018)

Publications

Web links

Individual evidence

  1. ^ Helmholtz Center Munich
  2. ↑ Study overview
personal data
SURNAME Ziegler, Anette-Gabriele
BRIEF DESCRIPTION German diabetologist
DATE OF BIRTH June 13, 1958
PLACE OF BIRTH Munich